The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

PhRMA tussles with HHS & ICER poses an existential question

By Damian Garde

The READOUT
The Readout

Retracting stem cell science & Trump’s pricing transparency plan

By Damian Garde

The READOUT
The Readout

Biotech’s no-good week & the triumph of unicorns

By Damian Garde

The READOUT
The Readout

Biotech’s red-number day & good news for machine learners

By Damian Garde

The READOUT
The Readout

A hiccup for the next idea in cancer & another unicorn IPO

By Damian Garde

The READOUT
The Readout

IPO haves and have-nots & prenatal CRISPR

By Damian Garde

The READOUT
The Readout

A black box warning & Gottlieb on cybersecurity

By Damian Garde

The READOUT
The Readout

Arrowhead’s bombast & Blackstone’s new life sciences firm

By Damian Garde

The READOUT
The Readout

Sarepta’s tantalizing data & a boom in synthetic bio

By Damian Garde

The READOUT
The Readout

Digital health is hot & Nobel Prizes are hard

By Damian Garde

The READOUT
The Readout

A peculiar CAR-T case & echoes of Tuskegee

By Damian Garde

The READOUT
The Readout

Free migraine drugs & MSK gives back

By Damian Garde

The Readout

Never miss an episode of our weekly biotech podcast

By Damian Garde

The READOUT
The Readout

VC cartels & spit takes on spit tests

By Damian Garde

The READOUT
The Readout

Faltering IPOs & the price of pharma incentives

By Damian Garde

The READOUT
The Readout

How to avoid biotech hype & an update on the third quarter

By Damian Garde

The READOUT
The Readout

An IPO black sheep & a pivot to weed

By Damian Garde

The READOUT
The Readout

Modeling Alzheimer’s & a watershed moment for Amarin

By Damian Garde

The READOUT
The Readout

A questionable cancer claim & NASH is the new blockchain

By Damian Garde

The READOUT
The Readout

Tumultuous ticker tape & the digital health bubble

By Damian Garde

The READOUT
The Readout

PhRMA’s unexpected advocacy & biotech’s IPO momentum

By Damian Garde

The READOUT
The Readout

Sarepta redux & CRISPR for diabetes

By Damian Garde

The READOUT
The Readout

Phillip Frost’s fate & Cochrane turmoil

By Damian Garde

The READOUT
The Readout

Geron’s waiting game & OPKO’s paralysis

By Damian Garde

The READOUT
The Readout

Moderna’s long-awaited IPO & Global Blood’s risky gambit

By Damian Garde

The READOUT
The Readout

A clinical trial cheat sheet & a 400 percent price hike

By Damian Garde

The READOUT
The Readout

Fact-checking an ad war & a wrench in CAR-T

By Damian Garde

The Readout

Your burning biotech questions for 2018 answered, and more alarm bells for CRISPR

By Damian Garde

The READOUT
The Readout

What’s next for biotech’s most-watched companies & Takeda family drama

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy